In particular, novel USP7 inhibitors have demonstrated multifaceted efficacy by not only inducing p53-dependent senescence and apoptosis in MDM2-overexpressing malignancies but also by remodeling the tumor microenvironment to activate immune responses and promoting bone regeneration in senile osteoporosis models [111,112,113]. Here, TP53 is linked to neoplasm.